New 52-week Phase III data for Incyte Corporation’s topical JAK inhibitor Opzelura (ruxolitinib) for vitiligo show no new safety signals, despite lingering concerns about the safety and tolerability of the JAK inhibitor class. The data also showed increased efficacy, and both the safety and efficacy could support the longer-term use that will be needed in vitiligo.
Incyte is presenting the one-year data from the TRuE-V clinical trial program at the American Academy of Dermatology annual meeting, taking place 25-29 March
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?